Clal Biotechnology Industries

TytoCare Ltd. is a healthcare technology company that specializes in developing handheld devices and mobile applications for remote medical examinations. Founded in 2011 and headquartered in Netanya, Israel, with an additional office in New York, TytoCare enables users to perform self-examinations and connect with healthcare professionals for on-demand diagnoses and prescriptions. The company's product offerings include TytoHome for consumers, TytoPro for healthcare professionals, and TytoClinic for remote care settings. These solutions encompass a modular examination tool that allows users to assess various health parameters, including heart and lung function, skin, throat, ears, and body temperature. TytoCare's platform also features a telehealth system for sharing examination data, conducting live video consultations, and utilizing a cloud-based repository with analytics. With built-in guidance technology and machine learning, TytoCare aims to enhance the accuracy and accessibility of healthcare services. The company maintains a strategic partnership with Novant Health to further its mission of facilitating remote healthcare.

Sight Diagnostics Ltd. is a medical device company based in Tel Aviv, Israel, that specializes in blood diagnostics using advanced computer vision technology. The company focuses on improving health outcomes with rapid, accurate, and convenient diagnostic solutions. His flagship product, Parasight, is a malaria detection device that has performed nearly one million tests across 24 countries, though it is not available for sale in the United States. Sight Diagnostics has also developed Sight OLO, an FDA-cleared blood analyzer that requires only two drops of blood to deliver lab-grade Complete Blood Count results within minutes. Combining machine vision, AI, and innovations in multiple scientific fields, Sight Diagnostics aims to facilitate effective healthcare delivery and expand its commercial presence across five continents.

Cadent Therapeutics, Inc. is a precision neuroscience company focused on developing innovative therapies for serious neurological and psychiatric disorders. Founded in 2010 and based in Cambridge, Massachusetts, the company specializes in small molecule therapeutics that target NMDA receptors to address conditions such as depression, schizophrenia, Rett syndrome, and other cognitive and movement disorders. Cadent's approach combines target specificity, patient selection, and drug design to create allosteric modulators that can enhance neuronal firing regularity and restore brain rhythms. By leveraging novel quantitative endpoints, Cadent aims to develop first-in-class medications that improve cognitive and motor functions in patients, ultimately enhancing clinical outcomes for those suffering from various neurological diseases.

Elicio Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of amphiphile immunotherapies aimed at treating aggressive cancers. The company leverages its proprietary Amphiphile platform to deliver immunogens directly to the lymphatic system, enhancing the immune response and improving the body’s ability to fight cancer. Elicio's key products include ELI-002, an amphiphile vaccine targeting KRAS gene mutations to prevent recurrence in pancreatic, colorectal, and lung cancers, and ELI-001, which is designed for HPV-driven head and neck cancers. Elicio Therapeutics was founded in 2011 and was previously known as Vedantra Pharmaceuticals before rebranding in 2019. The company focuses on creating innovative immunotherapies for patients with limited treatment options and challenging cancer types.

Anchiano Therapeutics Ltd. is a preclinical biotechnology company focused on discovering, developing, and commercializing small molecule anti-cancer therapies. The company specializes in targeted cancer therapies designed to selectively destroy cancer cells while sparing healthy cells. Its primary development efforts are centered on the Pan-RAS Program, which identifies novel indene-based small molecules that inhibit activated RAS signaling, and the PDE10/ß-catenin program, aimed at selectively inhibiting PDE10 and suppressing Wnt/APC/ß-catenin signaling. Anchiano Therapeutics has a collaboration agreement with ADT Pharmaceuticals to further research these programs. Originally founded in 2004 as BioCancell Ltd., the company rebranded in July 2018 and is headquartered in Cambridge, Massachusetts. The company has developed drug candidates such as BC-819 and BC-821, with BC-819 having completed a Phase IIb clinical trial for bladder cancer.

Colospan Ltd is a clinical-stage medical device company based in Kfar Saba, Israel, specializing in healthcare equipment for colorectal surgeries. Established in 2010, Colospan develops proprietary technology aimed at preventing anastomotic leaks and the need for diverting colonic stomas after intestinal surgeries. The company’s lead product is a single-use, temporary intraluminal bypass device designed to reduce contact between fecal matter and the anastomotic site, thereby mitigating the complications associated with such leaks. This innovative device is intended to prevent or delay the need for colostomy after surgeries performed for severe intestinal inflammatory diseases and colorectal cancer. Colospan’s technology seeks to enhance patient recovery by reducing the risk of life-threatening symptoms associated with clinical anastomotic leaks and minimizing post-operative complications, ultimately supporting the well-being of patients following significant surgical procedures.

Gamida Cell Ltd., established in 1998 and headquartered in Jerusalem, Israel, is a clinical-stage biopharmaceutical company focused on developing advanced cell therapies to treat blood cancers and serious blood diseases. The company's lead product candidate, omidubicel, is an expanded hematopoietic stem cell therapy derived from umbilical cord blood, currently in Phase 3 studies for patients with high-risk hematologic malignancies and severe aplastic anemia. Additionally, Gamida Cell is developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase 1/2 trials for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Both candidates leverage the company's proprietary expansion platform based on nicotinamide to enhance cell properties and therapeutic potential.

Pi-Cardia is a medical device start-up focused on developing an innovative low-profile catheter for the treatment of aortic stenosis. The company's proprietary technology utilizes a trans-femoral catheter that incorporates nitinol elements to deliver mechanical impact, creating fractures in calcified heart valves without damaging the surrounding soft tissue. This rapid treatment approach aims to enhance the effective orifice area of the valve, providing a cost-effective and durable solution that eliminates the need for valve replacement. By addressing the challenges associated with aortic stenosis, Pi-Cardia seeks to improve patient outcomes and streamline the treatment process for healthcare providers.

Neon Therapeutics is a clinical-stage biopharmaceutical company specializing in neoantigen-targeted therapies aimed at revolutionizing cancer treatment. By harnessing the immune system's ability to recognize and attack neoantigens, the company seeks to develop innovative therapies that improve patient outcomes. Its product pipeline includes NEO-PV-01, NEO-PTC-01, and NEO-SV-01, which are designed to enhance the immune response against tumors. Through its focused research and development efforts, Neon Therapeutics is committed to advancing the field of immuno-oncology and providing new options for cancer patients.

Sight Diagnostics Ltd. is a medical device company based in Tel Aviv, Israel, that specializes in blood diagnostics using advanced computer vision technology. The company focuses on improving health outcomes with rapid, accurate, and convenient diagnostic solutions. His flagship product, Parasight, is a malaria detection device that has performed nearly one million tests across 24 countries, though it is not available for sale in the United States. Sight Diagnostics has also developed Sight OLO, an FDA-cleared blood analyzer that requires only two drops of blood to deliver lab-grade Complete Blood Count results within minutes. Combining machine vision, AI, and innovations in multiple scientific fields, Sight Diagnostics aims to facilitate effective healthcare delivery and expand its commercial presence across five continents.

CureTech Ltd. is a biotechnology company based in Yavne, Israel, specializing in the development of immune modulating products aimed at treating and controlling cancer. Founded in 2001, the company focuses on creating antibodies and peptide-therapeutics designed to enhance the immune response against various tumors. One of its notable products is pidilizumab (CT-011), a humanized monoclonal antibody that demonstrates effective anti-cancer activity across a range of mouse and human tumors. CureTech's innovative approach seeks to combat tumor growth and metastasis by leveraging the body's immune system to target and eliminate cancer cells.

MediWound Ltd. is an integrated biopharmaceutical company based in Yavne, Israel, that specializes in developing, manufacturing, and commercializing innovative therapeutic products for severe burns and chronic wounds. Founded in 2000, the company is known for its flagship product, NexoBrid, which is an FDA-approved biopharmaceutical designed for the removal of eschar in adults with deep partial- and full-thickness thermal burns, offering a less invasive alternative to surgical interventions. MediWound also advances other product candidates, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic and hard-to-heal wounds, and MWPC003 for connective tissue disorders. The company aims to address significant unmet medical needs in these areas and improve patient outcomes.

Cadent Therapeutics, Inc. is a precision neuroscience company focused on developing innovative therapies for serious neurological and psychiatric disorders. Founded in 2010 and based in Cambridge, Massachusetts, the company specializes in small molecule therapeutics that target NMDA receptors to address conditions such as depression, schizophrenia, Rett syndrome, and other cognitive and movement disorders. Cadent's approach combines target specificity, patient selection, and drug design to create allosteric modulators that can enhance neuronal firing regularity and restore brain rhythms. By leveraging novel quantitative endpoints, Cadent aims to develop first-in-class medications that improve cognitive and motor functions in patients, ultimately enhancing clinical outcomes for those suffering from various neurological diseases.

Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, founded in 2010. The company focuses on the development of innovative products for the treatment and prevention of neurodegenerative disorders. Its lead product candidate, Ladostigil, is designed for mild cognitive impairment and employs a combination of neuroprotective mechanisms, including the reduction of oxidative stress, inhibition of pro-inflammatory cytokines, and modulation of microglial activation. Avraham Pharmaceuticals has raised funding to support clinical trials, including a European Phase II proof-of-concept efficacy trial for Alzheimer's disease, aimed at validating the effectiveness of Ladostigil.

Gamida Cell Ltd., established in 1998 and headquartered in Jerusalem, Israel, is a clinical-stage biopharmaceutical company focused on developing advanced cell therapies to treat blood cancers and serious blood diseases. The company's lead product candidate, omidubicel, is an expanded hematopoietic stem cell therapy derived from umbilical cord blood, currently in Phase 3 studies for patients with high-risk hematologic malignancies and severe aplastic anemia. Additionally, Gamida Cell is developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase 1/2 trials for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Both candidates leverage the company's proprietary expansion platform based on nicotinamide to enhance cell properties and therapeutic potential.

Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, founded in 2010. The company focuses on the development of innovative products for the treatment and prevention of neurodegenerative disorders. Its lead product candidate, Ladostigil, is designed for mild cognitive impairment and employs a combination of neuroprotective mechanisms, including the reduction of oxidative stress, inhibition of pro-inflammatory cytokines, and modulation of microglial activation. Avraham Pharmaceuticals has raised funding to support clinical trials, including a European Phase II proof-of-concept efficacy trial for Alzheimer's disease, aimed at validating the effectiveness of Ladostigil.

Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, founded in 2010. The company focuses on the development of innovative products for the treatment and prevention of neurodegenerative disorders. Its lead product candidate, Ladostigil, is designed for mild cognitive impairment and employs a combination of neuroprotective mechanisms, including the reduction of oxidative stress, inhibition of pro-inflammatory cytokines, and modulation of microglial activation. Avraham Pharmaceuticals has raised funding to support clinical trials, including a European Phase II proof-of-concept efficacy trial for Alzheimer's disease, aimed at validating the effectiveness of Ladostigil.

ProtAb develops therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune and inflammatory diseases. Its first product, Prozumab, is a monoclonal antibody with a novel mechanism of action. It is currently in late-stage preclinical development for the treatment of inflammatory bowel disease or IBD, ulcerative colitis or UC, and rheumatoid arthritis or RA. It operates as a subsidiary of Hadasit Bio-Holdings. HBL is a publicly traded subsidiary of Hadasit, the technology transfer company of the Hadassah University Hospital in Jerusalem in Israel.

Aposense Ltd. is a biopharmaceutical company based in Petah Tikva, Israel, specializing in the development of innovative drugs that leverage the unique structural and electrical properties of biological membranes. Founded in 1996, Aposense focuses on creating molecular nano-motors capable of harnessing energy from intra-membrane electric fields to facilitate the delivery of genetic drugs, such as siRNA, into cells. The company has developed a platform technology known as Apo-Si, which supports targeted therapy and real-time clinical imaging of disease activity, particularly in oncology, cardiology, and neurology. Aposense is also advancing its proprietary drug candidate, ATT-11T, a conjugate designed to treat solid tumors by combining a molecular nano-motor with SN-38, the active component of irinotecan. With its commitment to transforming apoptosis targeting into practical applications, Aposense is at the forefront of integrating advanced therapeutic strategies into personalized patient care.

Polyheal Ltd. is an advanced medical device company based in Yavne, Israel, founded in 1996. The company specializes in developing, manufacturing, and commercializing wound care products using its proprietary negatively-charged microsphere (NCM) technology. This innovative approach enables the effective treatment of various types of wounds, including chronic wounds, diabetic foot ulcers, and pressure-induced ulcers, without the need for pharmacologically active agents. Polyheal's sterile liquid suspension actively promotes the healing process in complex cases, such as wounds with exposed bone and tendons. In addition to its product offerings, the company provides training and education services to enhance patient care. Polyheal primarily serves patients in Europe and Israel.

D-Pharm (TASE: DPRM) is a drug-development company focused on innovative drugs for the treatment of central nervous system (CNS) conditions. The Company’s particular area of interest is in developing innovative medicine for degenerative and age-related disorders.

Compugen Ltd. is a clinical-stage therapeutic discovery and development company headquartered in Holon, Israel. It specializes in the research, development, and commercialization of novel therapeutic candidates primarily in the field of cancer immunotherapy. The company's immuno-oncology pipeline includes several clinical-stage programs, such as COM701, an anti-PVRIG antibody, and COM902, which targets TIGIT, both designed for the treatment of solid tumors. Compugen employs advanced computational methods for drug discovery, utilizing in silico techniques to predict and select promising drug targets, followed by rigorous experimental validation. The company collaborates with major pharmaceutical partners, including Bayer Pharma AG and Bristol-Myers Squibb, to enhance its research and development efforts. Compugen's focus on innovative therapeutic solutions aims to address significant unmet medical needs in oncology, leveraging its unique predictive capabilities and a robust pipeline of early-stage programs targeting immune resistance mechanisms.